Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244153 | 0.89 | SRD5A2 (0.43) | KDM4EALDH1A1HSD17B10RAB9AMEN1 | |
| SCHEMBL4831486 | 0.83 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2JAK2JAK1TYK2 | |
| SCHEMBL732858 | 0.82 | KMT2A (0.37) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL3945086 | 0.81 | RPS6KA3 (0.40) | RPS6KA3BCAT2ROCK2PIM1PIM3 | |
| SCHEMBL4823385 | 0.81 | RPS6KA3 (0.41) | RPS6KA3NPC1RAB9ARPS6KA2JAK2 | |
| SCHEMBL4829827 | 0.81 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2JAK2JAK1TYK2 | |
| SCHEMBL5329442 | 0.79 | SRD5A2 (0.39) | RPS6KA3BCAT2ROCK2PIM1PIM3 | |
| SCHEMBL50820 | 0.78 | RPS6KA3 (0.49) | RPS6KA3BCAT2ROCK2PIM1PIM3 | |
| SCHEMBL4822220 | 0.77 | RPS6KA3 (0.40) | RPS6KA3ROCK2PIM1PIM3BAZ2B | |
| SCHEMBL50474 | 0.72 | RPS6KA3 (0.39) | RPS6KA3ROCK2PIM1PIM3BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183252-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | claimed |
| EP-2178878-B1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | claimed |
| EP-2183252-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-05-12 | — | — | EP | claimed |
| EP-2178878-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-04-28 | — | — | EP | claimed |
| US-7652004-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | claimed |
| US-7642251-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | claimed |
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | claimed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | claimed |
| WO-2009023487-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-19 | — | — | WO | claimed |
| US-20090042860-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | claimed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | claimed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2178878-B1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8143243-B2 | 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2280975-A1 | 7H-INDOLOÝ2,1-A¨Ý2¨BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA3 1278/4885BCAT2 548/4885ROCK2 3590/4885 |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | RPS6KA3 2580/4885BCAT2 1095/4885ROCK2 4166/4885 |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA3 1970/4885BCAT2 1750/4885ROCK2 3376/4885 |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA3 1278/4885BCAT2 548/4885ROCK2 3590/4885 |
| US-20090042860-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA3 1278/4885BCAT2 548/4885ROCK2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.